tirzepatide surpass 5 Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Systolic blood pressure reduction with

Restores youthful density and elasticity with iFirm Technology

Experiencing odd tastes on Ozempic

Sounds like a pharmaceutical spelling bee, right

This approval represents a significant shift in how physicians can approach OSA treatment, particularly for patients who struggle with CPAP or haven't found success with traditional therapies

Retatrutide is Eli Lillys once weekly injectable that targets three pathways at the same time, GLP-1, GIP, and glucagon

Insurers have plenty to consider when weighing coverage fornew weight loss medications, andthat includes the need tocarefully coordinate distribution with their pharmacy benefit m | Payers need to work closely with PBMs to coordinate coverage decisions about Ozempic and other weight loss drugs, a new guide advises.